{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:46:02Z","timestamp":1785735962068,"version":"3.56.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood purification plays an important role in the treatment of severe acute pancreatitis. Extracorporeal blood anticoagulation is an important strategy to achieve smooth circulation in blood purification circuits. We aimed to investigate the efficacy, safety, and impact on circulating cytokines of using heparin or nafamostat mesylate anticoagulation in patients with severe acute pancreatitis during continuous renal replacement therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a single-center randomized controlled study. We plan to recruit adult patients with severe acute pancreatitis from intensive care units for this study. Participants who met the criteria were randomly assigned in a 1:1 ratio, with one group using heparin anticoagulation during continuous renal replacement therapy and the other group using nafamostat mesylate anticoagulation. The primary outcome measure was mean filter life. Secondary outcome measures included changes in Sequential Organ Failure Assessment (SOFA), the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and inflammatory factors (CRP, PCT, IL-6, IL-8, IL-10, TNF-\u03b1) compared with baseline levels on days 1, 3, 5, and 7 after treatment, time to successful initiation of enteral nutrition, blood transfusion requirements, ICU length of stay and total hospitalization days, and follow-up of patients\u2019 blood purification dependency rate and all-cause mortality at 28 days. Safety indicators include the occurrence of any bleeding events (defined by ISTH criteria), filter clotting, and the incidence of heparin-induced thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this study are expected to provide guidance for the selection of anticoagulant drugs for critically ill patients with severe acute pancreatitis who receive continuous renal replacement Therapy, and to clarify the optimal anticoagulation strategy for this population, thereby optimizing clinical practice for treating SAP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      ], identifier [ChiCTR2500 111161]\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1868927","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:30:52Z","timestamp":1785735052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: protocol for a randomized controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Hui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Hangzhou Lin\u2019an Traditional Chinese Medicine Hospital, Hangzhou","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital, Weifang","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital, Weifang","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital, Weifang","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital, Weifang","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Weifang People\u2019s Hospital, Weifang","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2020.20317","article-title":"Acute pancreatitis: a review.","volume":"325","author":"Mederos","year":"2021","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.gastro.2024.02.052","article-title":"Diagnosis and management of acute pancreatitis.","volume":"167","author":"Trikudanathan","year":"2024","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1007\/s11427-024-2900-6","article-title":"Global burden and characterization of hypertriglyceridemia-induced acute pancreatitis: results from a systematic review and a multi-center cohort study.","volume":"68","author":"Fan","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.pan.2020.03.001","article-title":"Etiology and mortality in severe acute pancreatitis: a multicenter study in Japan.","volume":"20","author":"Yasuda","year":"2020","journal-title":"Pancreatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.asjsur.2023.07.063","article-title":"Hospital mortality rate and predictors in acute pancreatitis in Poland: a single-center experience.","volume":"47","author":"Nawacki","year":"2024","journal-title":"Asian J Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1053\/j.gastro.2018.12.041","article-title":"Organ failure due to systemic injury in acute pancreatitis.","volume":"156","author":"Garg","year":"2019","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1499-3872(16)60163-7","article-title":"Severe acute pancreatitis: pathogenesis, diagnosis and surgical management.","volume":"16","author":"Portelli","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1477160","DOI":"10.3389\/fimmu.2024.1477160","article-title":"Coagulopathy and acute pancreatitis: pathophysiology and clinical treatment.","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41575-019-0158-2","article-title":"New insights into acute pancreatitis.","volume":"16","author":"Lee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gtc.2024.09.001","article-title":"Organ failure and prediction of severity in acute pancreatitis.","volume":"54","author":"Mahapatra","year":"2025","journal-title":"Gastroenterol Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.12659\/MSM.910099","article-title":"Changes of serum procalcitonin (PCT), c-reactive protein (CRP), interleukin-17 (IL-17), interleukin-6 (IL-6), high mobility group protein-b1 (HMGB1) and d-dimer in patients with severe acute pancreatitis treated with continuous renal replacement therapy (CRRT) and its clinical significance.","volume":"24","author":"Gao","year":"2018","journal-title":"Med Sci Monit"},{"key":"B12","first-page":"8067","article-title":"Effect of continuous renal replacement therapy adjuvant to broad-spectrum enzyme inhibitors on the efficacy and inflammatory cytokines in patients with severe acute pancreatitis.","volume":"13","author":"Zhu","year":"2021","journal-title":"Am J Transl Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s12876-025-04198-y","article-title":"Application of continuous renal replacement therapy (CRRT) in patients with severe acute pancreatitis: an analytical study.","volume":"25","author":"Weng","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.3390\/polym14122470","article-title":"Heparin protects severe acute pancreatitis by inhibiting HMGB-1 active secretion from macrophages.","volume":"14","author":"Yang","year":"2022","journal-title":"Polymers."},{"key":"B15","first-page":"103","article-title":"Protective and therapeutic effect of heparin in acute pancreatitis.","volume":"59","author":"Ceranowicz","year":"2008","journal-title":"J Physiol Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"106621","DOI":"10.1016\/j.ijsu.2022.106621","article-title":"Impact of low-molecular-weight heparin in the treatment of moderately severe and severe acute pancreatitis; a randomized, single blind, phase 3 control trial.","volume":"101","author":"Patil","year":"2022","journal-title":"Int J Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13054-023-04519-1","article-title":"Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials.","volume":"27","author":"Zhou","year":"2023","journal-title":"Crit Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.23876\/j.krcp.23.310","article-title":"The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety.","volume":"43","author":"Kim","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"704e","DOI":"10.1053\/j.gastro.2017.10.018","article-title":"Cathepsin B-mediated activation of trypsinogen in endocytosing macrophages increases severity of pancreatitis in mice.","volume":"154","author":"Sendler","year":"2018","journal-title":"Gastroenterology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00535-019-01644-z","article-title":"Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.","volume":"55","author":"Hirota","year":"2020","journal-title":"J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000085278","article-title":"Pancreatic proteases in serum induce leukocyte-endothelial adhesion and pancreatic microcirculatory failure.","volume":"5","author":"Keck","year":"2005","journal-title":"Pancreatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/mpa.0b013e31802d4136","article-title":"Extrapancreatic inflammation on abdominal computed tomography as an early predictor of disease severity in acute pancreatitis: evaluation of a new scoring system.","volume":"34","author":"De Waele","year":"2007","journal-title":"Pancreas"},{"key":"B24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20132012: revision of the Atlanta classification and definitions by international consensus.","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.22543\/2392-7674.1476","article-title":"Effect of continuous renal replacement therapy on serum levels of inflammatory cytokines\/interleukin-17 in severe acute pancreatitis.","volume":"11","author":"Iosif","year":"2024","journal-title":"J Mind Med Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e939314","DOI":"10.12659\/MSM.939314","article-title":"Clinical evaluation of continuous renal replacement therapy combined with peritoneal lavage for severe acute pancreatitis: a retrospective cohort study.","volume":"29","author":"Jiang","year":"2023","journal-title":"Med Sci Monit"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.2147\/JIR.S512553","article-title":"Association between the systemic inflammation response index and severity of acute pancreatitis: a retrospective cohort study.","volume":"18","author":"Wu","year":"2025","journal-title":"J Inflamm Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0296641","DOI":"10.1371\/journal.pone.0296641","article-title":"Evaluation of the therapeutic efficiency and efficacy of blood purification in the treatment of severe acute pancreatitis.","volume":"19","author":"Huang","year":"2024","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3760\/cma.j.cn121430-20240408-00317","article-title":"[Study on the clinical effect of initiating continuous blood purification at different times for severe acute pancreatitis].","volume":"36","author":"Chen","year":"2024","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"B30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.chest.2018.09.004","article-title":"Continuous renal replacement therapy: who, when, why, and how.","volume":"155","author":"Tandukar","year":"2019","journal-title":"Chest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.3390\/jcm14186647","article-title":"Value of continuous hemofiltration in patients with severe acute pancreatitis at onset: single centre experience on 48 patients.","volume":"14","author":"Saullo","year":"2025","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13054-022-03910-8","article-title":"How to prolong filter life during continuous renal replacement therapy?","volume":"26","author":"Tsujimoto","year":"2022","journal-title":"Crit Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13017-024-00558-3","article-title":"Effectiveness and safety of low molecular weight heparin in the management of acute pancreatitis: a systematic review and meta-analysis.","volume":"19","author":"Podda","year":"2024","journal-title":"World J Emerg Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jointm.2024.02.003","article-title":"Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate.","volume":"4","author":"He","year":"2024","journal-title":"J Intensive Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/0886022X.2022.2105233","article-title":"Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis.","volume":"44","author":"Lin","year":"2022","journal-title":"Ren Fail"},{"key":"B36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0003-4975(03)01513-3","article-title":"Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.","volume":"77","author":"Kaminishi","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00011-023-01794-0","article-title":"Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.","volume":"72","author":"Chen","year":"2023","journal-title":"Inflamm Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4196\/kjpp.2015.19.3.229","article-title":"Nafamostat mesilate inhibits tnf-\u03b1-induced vascular endothelial cell dysfunction by inhibiting reactive oxygen species production.","volume":"19","author":"Kang","year":"2015","journal-title":"Korean J Physiol Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:30:54Z","timestamp":1785735054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1868927"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1868927","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1868927"}}